Literature DB >> 7989764

An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4.

F Pericle1, M Giovarelli, M P Colombo, G Ferrari, P Musiani, A Modesti, F Cavallo, F Di Pierro, F Novelli, G Forni.   

Abstract

A retroviral infection was used to introduce the cDNA coding for mouse IL-4 into the parental cells of a spontaneous adenocarcinoma of BALB/c mice (TS/A-pc). Four clones releasing between 5 to 40 U of IL-4 (10(5) cells) in 48 h culture were selected. The secretion of IL-4 does not affect their in vitro growth, whereas their ability to form tumor in vivo inversely correlates with the amount of IL-4 secreted. Although morphologic observation suggested that the rejection of clone D5.40 cells (releasing 40 U of IL-4) depends on eosinophil cytolysis, lymphocyte depletion experiments showed that this required CD8+ lymphocyte guidance. Mice that had rejected D5.40 cells were immune to a subsequent challenge with TS/A-pc. This memory rests on the interaction between noncytotoxic lymphocytes, eosinophils, and IgG1 and IgE anti-TS/A Abs. Comparison of these memory mechanisms with those elicited by IL-2 gene-transduced TS/A cells shows that the kind of cytokine released by the tumor cells determines the type of response. This Th2 memory seems to be more efficient in protecting against a subsequent challenge of TS/A-pc than the Th1-type memory elicited by IL-2 gene-transduced TS/A cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989764

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

Review 1.  Eosinophils in innate immunity: an evolving story.

Authors:  Revital Shamri; Jason J Xenakis; Lisa A Spencer
Journal:  Cell Tissue Res       Date:  2010-11-03       Impact factor: 5.249

Review 2.  ITCH as a potential therapeutic target in human cancers.

Authors:  Qing Yin; Clayton J Wyatt; Tao Han; Keiran S M Smalley; Lixin Wan
Journal:  Semin Cancer Biol       Date:  2020-03-10       Impact factor: 15.707

Review 3.  Immunotherapy I: Cyclosine gene transfer strategies.

Authors:  M P Colombo; G Forni
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

4.  IL-17-dependent, IFN-gamma-independent tumor rejection is mediated by cytotoxic T lymphocytes and occurs at extraocular sites, but is excluded from the eye.

Authors:  Terry G Coursey; Peter W Chen; Jerry Y Niederkorn
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

Review 5.  Immunotherapy III: Combinatorial molecular immunotherapy--a synthesis and suggestions.

Authors:  R G Vile; H Chong
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

6.  Paracrine effects of IL-4 transfection on TS/A adenocarcinoma cells mediate reduced in vivo growth.

Authors:  S Pacor; R Gagliardi; P Spessotto; G Zabucchi; G Sava
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

Review 7.  Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions.

Authors:  Hao-Wei Wang; Johanna A Joyce
Journal:  Cell Cycle       Date:  2010-12-15       Impact factor: 4.534

8.  Monocyte activation in patients with non-seminomatous germ cell tumour of the testis before and after tumour eradication.

Authors:  A Trulson; S Nilsson; P Venge
Journal:  J Clin Pathol       Date:  1996-05       Impact factor: 3.411

9.  The tumor protection effect of high-frequency administration of whole tumor cell vaccine and enhanced efficacy by the protein component from Agrocybe aegerita.

Authors:  Yi Liang; Hui Sun
Journal:  Int J Clin Exp Med       Date:  2015-05-15

10.  Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas.

Authors:  Claudia Curcio; Emma Di Carlo; Raphael Clynes; Mark J Smyth; Katia Boggio; Elena Quaglino; Michela Spadaro; Mario P Colombo; Augusto Amici; Pier-Luigi Lollini; Piero Musiani; Guido Forni
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.